Abstract
The mechanisms underlying responses to drugs of abuse have been widely investigated; however, less is known about pathways normally protective against the development of drug reinforcement. These pathways are also important since they may regulate individual differences in vulnerability to addiction. The neuropeptide galanin and its binding sites are expressed in brain areas important for drug reward. Previous studies have shown that centrally infused galanin attenuates morphine place preference and peripheral injection of galnon, a galanin agonist, decreases opiate withdrawal signs. The current studies in galanin knockout (GKO) mice examined the hypothesis that galanin is an endogenous negative regulator of opiate reward and identified downstream signaling pathways regulated by galanin. We show that GKO mice demonstrate increased locomotor activation following morphine administration, which is inhibited by acute administration of galnon. GKO mice also show enhanced morphine place preference, supporting the idea that galanin normally antagonizes opiate reward. In addition, morphine-induced ERK1/2 phosphorylation was increased in the VTA of both wild-type and GKO mice, but only the GKO mice showed increases in ERK1/2 and CREB phosphorylation in the amygdala or nucleus accumbens. Furthermore, a single systemic injection of galnon in GKO mice was sufficient to reverse some of the biochemical changes brought about by morphine administration. These data suggest that galanin normally attenuates behavioral and neurochemical effects of opiates; thus, galanin agonists may represent a new class of therapeutic targets for opiate addiction.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abramov U, Florén A, Echevarria DJ, Brewer A, Manuzon H, Robinson JK et al (2004). Regulation of feeding by galnon. Neuropeptides 38: 55–61.
Antoniou K, Kehr J, Snitt K, Ogren SO (1997). Differential effects of the neuropeptide galanin on striatal acetylcholine release in anaesthetized and awake rats. Br J Pharmacol 121: 1180–1186.
Belcheva MM, Clark AL, Haas PD, Serna JS, Hahn JW, Kiss A et al (2005). Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem 280: 27662–27669.
Belcheva MM, Szucs M, Wang D, Sadee W, Coscia CJ (2001). Mu-opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation. J Biol Chem 276: 33847–33853.
Berhow MT, Hiroi N, Nestler EJ (1996). Regulation of ERK (extracellular signal regulated kinase), part of the neurotrophin signal transduction cascade, in the rat mesolimbic dopamine system by chronic exposure to morphine or cocaine. J Neurosci 16: 4707–4715.
Berthold M, Kahl U, Jureus A, Kask K, Nordvall G, Langel Ü et al (1997). Mutagenesis and ligand modification studies on galanin binding to its GTP-binding-protein-coupled receptor GalR1. Eur J Biochem 249: 601–606.
Brunzell DH, Chang JR, Schneider B, Olausson P, Taylor JR, Picciotto MR (2006). Beta2-subunit-containing nicotinic acetylcholine receptors are involved in nicotine-induced increases in conditioned reinforcement but not progressive ratio responding for food in C57BL/6 mice. Psychopharmacology 184: 328–338.
Burgevin MC, Loquet I, Quarteronet D, Habert-Ortoli E (1995). Cloning, pharmacological characterization, and anatomical distribution of a rat cDNA encoding for a galanin receptor. J Mol Neurosci 6: 33–41.
Carlezon Jr WA, Duman RS, Nestler EJ (2005). The many faces of CREB. Trends Neurosci 28: 436–445.
Carrigan KA, Dykstra LA (2007). Behavioral effects of morphine and cocaine in M1 muscarinic acetylcholine receptor-deficient mice. Psychopharmacology (Berl) 191: 985–993.
Chang CK, Wang NL, Lin MT (2004). Inhibition of the dopamine system in rat amygdala attenuates the picrotoxin-induced locomotor hyperactivity and hypertension. Clin Exp Pharmacol Physiol 31: 284–288.
Chao J, Nestler EJ (2004). Molecular neurobiology of drug addiction. Annu Rev Med 55: 113–132.
Chao JR, Ni YG, Bolanos CA, Rahman Z, DiLeone RJ, Nestler EJ (2002). Characterization of the mouse adenylyl cyclase type VIII gene promoter: regulation by cAMP and CREB. Eur J Neurosci 16: 1284–1294.
Chartoff EH, Papadopoulou M, Konradi C, Carlezon Jr WA (2003). Dopamine-dependent increases in phosphorylation of cAMP response element binding protein (CREB) during precipitated morphine withdrawal in primary cultures of rat striatum. J Neurochem 87: 107–118.
Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274–5278.
Eidelberg E, Erspamer R (1975). Dopaminergic mechanisms of opiate actions in brain. J Pharmacol Exp Ther 192: 50–57.
Eitan S, Bryant CD, Saliminejad N, Yang YC, Vojdani E, Keith Jr D et al (2003). Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization. J Neurosci 23: 8360–8369.
Ellis Y, Davies JA (1994). The effect of neuropeptides on the release of neurotransmitter amino acids from rat striatum. Neuropeptides 26: 65–69.
Flören A, Sollenberg U, Lundstrom L, Zorko M, Stojan J, Budihna M et al (2005). Multiple interaction sites of galnon trigger its biological effects. Neuropeptides 39: 547–558.
Girault JA, Greengard P (2004). The neurobiology of dopamine signaling. Arch Neurol 61: 641–644.
Girault JA, Valjent E, Caboche J, Herve D (2007). ERK2: a logical AND gate critical for drug-induced plasticity? Curr Opin Pharmacol 7: 77–85.
Gustafson EL, Smith KE, Durkin MM, Gerald C, Branchek TA (1996). Distribution of a rat galanin receptor mRNA in rat brain. NeuroReport 7: 953–957.
Hawes JJ, Narasimhaiah R, Picciotto MR (2006a). Galanin and galanin-related peptide modulate neurite outgrowth via PKC-mediated activation of ERK. Eur J Neurosci 23: 2937–2946.
Hawes JJ, Narasimhaiah R, Picciotto MR (2006b). Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures. J Neurochem 96: 1160–1168.
Hawes JJ, Picciotto MR (2004). Characterization of GalR1, GalR2, and GalR3 immunoreactivity in catecholaminergic nuclei of the mouse brain. J Comp Neurol 479: 410–423.
Hikida T, Kitabatake Y, Pastan I, Nakanishi S (2003). Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci USA 100: 6169–6173.
Kinney JW, Starosta G, Crawley JN (2003). Central galanin administration blocks consolidation of spatial learning. Neurobiol Learn Mem 80: 42–54.
Kolakowski Jr LF, O'Neill GP, Howard AD, Broussard SR, Sullivan KA, Feighner SD et al (1998). Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J Neurochem 71: 2239–2251.
Konradi C, Cole RL, Heckers S, Hyman SE (1994). Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci 14: 5623–5634.
Loh HH, Smith AP (1990). Molecular characterization of opioid receptors. Annu Rev Pharmacol Toxicol 30: 123–147.
Nestler EJ (2001). Molecular neurobiology of addiction. Am J Addict 10: 201–217.
Oliverio A, Castellano C, Eleftheriou BE (1975). Morphine sensitivity and tolerance: a genetic investigation in the mouse. Psychopharmacologia 42: 219–224.
Olson VG, Heusner CL, Bland RJ, During MJ, Weinshenker D, Palmiter RD (2006). Role of noradrenergic signaling by the nucleus tractus solitarius in mediating opiate reward. Science 311: 1017–1020.
Ozaki S, Narita M, Narita M, Ozaki M, Khotib J, Suzuki T (2004). Role of extracellular signal-regulated kinase in the ventral tegmental area in the suppression of the morphine-induced rewarding effect in mice with sciatic nerve ligation. J Neurochem 88: 1389–1397.
Pandey SC, Chartoff EH, Carlezon Jr WA, Zou J, Zhang H, Kreibich AS et al (2005). CREB gene transcription factors: role in molecular mechanisms of alcohol and drug addiction. Alcohol Clin Exp Res 29: 176–184.
Pieribone VA, Xu ZQ, Zhang X, Grillner S, Bartfai T, Hökfelt T (1995). Galanin induces a hyperpolarization of norepinephrine-containing locus coeruleus neurons in the brainstem slice. Neuroscience 64: 861–874.
Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW et al (2007). Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon. Neuropeptides 41: 307–320.
Rezayof A, Zatali H, Haeri-Rohani A, Zarrindast MR (2006). Dorsal hippocampal muscarinic and nicotinic receptors are involved in mediating morphine reward. Behav Brain Res 166: 281–290.
Robbins TW, Everitt BJ (1996). Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 6: 228–236.
Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K et al (2002). Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA 99: 7136–7141.
Salzmann J, Marie-Claire C, Le Guen S, Roques BP, Noble F (2003). Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice. Br J Pharmacol 140: 831–838.
Shaw-Lutchman TZ, Barrot M, Wallace T, Gilden L, Zachariou V, Impey S et al (2002). Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal. J Neurosci 22: 3663–3672.
Suzuki T, Funada M, Narita M, Misawa M, Nagase H (1993). Morphine-induced place preference in the CXBK mouse: characteristics of mu opioid receptor subtypes. Brain Res 602: 45–52.
Tsuda K, Tsuda S, Nishio I, Masuyama Y, Goldstein M (1998). Effects of galanin on dopamine release in the central nervous system of normotensive and spontaneously hypertensive rats. Am J Hypertens 11: 1475–1479.
Valjent E, Caboche J, Vanhoutte P (2001). Mitogen-activated protein kinase/extracellular signal-regulated kinase induced gene regulation in brain: a molecular substrate for learning and memory? Mol Neurobiol 23: 83–99.
Valjent E, Corbille AG, Bertran-Gonzalez J, Herve D, Girault JA (2006a). Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. Proc Natl Acad Sci USA 103: 2932–2937.
Valjent E, Corvol JC, Trzaskos JM, Girault JA, Herve D (2006b). Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci 7: 20.
Valjent E, Pages C, Herve D, Girault JA, Caboche J (2004). Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur J Neurosci 19: 1826–1836.
Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol JC et al (2005). Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA 102: 491–496.
Wang HY, Wild KD, Shank RP, Lee DH (1999). Galanin inhibits acetylcholine release from rat cerebral cortex via a pertussis toxin-sensitive G(i) protein. Neuropeptides 33: 197–205.
Waters SM, Krause JE (2000). Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience 95: 265–271.
Widnell KL, Self DW, Lane SB, Russell DS, Vaidya VA, Miserendino MJ et al (1996). Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens. J Pharmacol Exp Ther 276: 306–315.
Williams JA, Su HS, Bernards A, Field J, Sehgal A (2001). A circadian output in Drosophila mediated by neurofibromatosis-1 and Ras/MAPK. Science 293: 2251–2256.
Wise RA (1987). The role of reward pathways in the development of drug dependence. Pharmacol Ther 35: 227–263.
Wu WP, Hao JX, Lundström L, Wiesenfeld-Hallin Z, Langel Ű, Bartfai T et al (2003). Systemic galnon, a low-molecular weight galanin receptor agonist, reduces heat hyperalgesia in rats with nerve injury. Eur J Pharmacol 482: 133–137.
Wynick D, Small CJ, Bloom SR, Pachnis V (1998). Targeted disruption of the murine galanin gene. Ann N Y Acad Sci 863: 22–47.
Zachariou V, Brunzell DH, Hawes J, Stedman DR, Bartfai T, Steiner RA et al (2003). The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proc Natl Acad Sci USA 100: 9028–9033.
Zachariou V, Parikh K, Picciotto MR (1999). Centrally administered galanin blocks morphine place preference in the mouse. Brain Res 831: 33–42.
Zarrindast MR, Bananej M, Khalilzadeh A, Fazli-Tabaei S, Haeri-Rohani A, Rezayof A (2006a). Influence of intracerebroventricular administration of dopaminergic drugs on morphine state-dependent memory in the step-down passive avoidance test. Neurobiol Learn Mem 86: 286–292.
Zarrindast MR, Farahmandfar M, Rostami P, Rezayof A (2006b). The influence of central administration of dopaminergic and cholinergic agents on morphine-induced amnesia in morphine-sensitized mice. J Psychopharmacol 20: 59–66.
Acknowledgements
This work was supported by grants DA15425 and DA00436 from the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Additional information
DISCLOSURE/CONFLICT OF INTEREST
The authors declare that over the last 3 years MRP has received compensation from Pfizer for scientific consultation unrelated to the present work. None of the other authors has any conflicts of interest.
Rights and permissions
About this article
Cite this article
Hawes, J., Brunzell, D., Narasimhaiah, R. et al. Galanin Protects Against Behavioral and Neurochemical Correlates of Opiate Reward. Neuropsychopharmacol 33, 1864–1873 (2008). https://doi.org/10.1038/sj.npp.1301579
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301579
Keywords
This article is cited by
-
Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase β/ζ Regulation in the Ventral Tegmental Area
Molecular Neurobiology (2017)
-
Hormones and Neuropeptide Receptor Heteromers in the Ventral Tegmental Area. Targets for the Treatment of Loss of Control of Food Intake and Substance Use Disorders
Current Treatment Options in Psychiatry (2017)
-
The effects of post-extinction exercise on cocaine-primed and stress-induced reinstatement of cocaine seeking in rats
Psychopharmacology (2015)
-
Pharmacogenetic Association of the Galanin Receptor (GALR1) SNP rs2717162 with Smoking Cessation
Neuropsychopharmacology (2012)
-
Galanin negatively modulates opiate withdrawal via galanin receptor 1
Psychopharmacology (2012)
